retatrutide clinical trials phase ESC 2024: improves lipid and cardiovascular risk profile in II trial Retatrutide Dosing Guide: 2mg–12mg Protocol

Herrmann C, Gke R, Richter G, Fehmann HC, Arnold R, Gke B

This bioactive lipid induces a powerful GPR119 mediated-GLP-1 secretion in vitro and ex-vivo from intestines of wild type, but not GPR119 deficient mice

How to ensure proper dosing during the first Ozempic injection

Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks

The maintenance phase challenge What happens when you stop: Appetite returns (gradually over weeks) Need to rely on habits built during weight loss Risk of regaining weight if not careful Success factors: How long you maintained at goal weight while on peptides Habits built during weight loss phase Continued protein intake and training Realistic expectations (some people maintain perfectly, others regain some) Tapering off GLP-1s Don't quit cold turkey: Gradually reduce dose over 4-8 weeks Example: 2.4mg 1.7mg 1mg 0.5mg 0.25mg stop This allows appetite to return gradually Gives you time to adjust habits While tapering: Monitor weight weekly If starting to regain, slow taper Maintain protein intake religiously Keep training consistent Long-term maintenance options Option 1: Cruise dose Stay on low dose GLP-1 indefinitely (0.25-0.5mg weekly) Maintains some appetite suppression Prevents regain Safer long-term than high doses Option 2: Cycle on/off 3-4 months on, 1-2 months off Return to peptides if weight creeps up 5+ pounds Allows body breaks from medication Option 3: Switch to sustainable peptides Transition from GLP-1s to CJC-1295/Ipamorelin Maintains metabolic benefits Supports muscle and recovery No appetite suppression (must rely on habits) Learn how to structure long-term protocols in our peptide cycle planning guide

Description Retatrutide is an advanced triple-agonist peptide developed by Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors